(Q54399172)

29 May 2018

title

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. (English)

1 reference

29 May 2018

0 references

1 reference

J A Frank

1 reference

29 May 2018

N Richert

1 reference

29 May 2018

B Lewis

1 reference

29 May 2018

C Bash

1 reference

29 May 2018

T Howard

1 reference

29 May 2018

R Civil

1 reference

29 May 2018

R Stone

1 reference

29 May 2018

J Eaton

1 reference

29 May 2018

H McFarland

1 reference

29 May 2018

T Leist

1 reference

29 May 2018

publication date

1 February 2002

1 reference

29 May 2018

Multiple Sclerosis Journal

published in

1 reference

29 May 2018

volume

1 reference

29 May 2018

issue

1 reference

29 May 2018

page(s)

24-29

1 reference

29 May 2018

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Growth factors and myelin regeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Insulin-like growth factors in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Multisection proton MR spectroscopic imaging of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Correspondence of closest gradient voxels--a robust registration algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS768OA

10.1191/1352458502MS768OA

21 January 2018

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018